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Blue dyes such as Patent Blue V (PBV) have been used in medical procedures for decades, and in the United Kingdom they are rou-
tinely utilised in sentinel lymph node biopsy (SLNB) for staging the axilla in early breast cancer. However, it has long been recognised 
that such dyes are associated with anaphylaxis. It has recently been estimated in a prospective study that allergy to PBV occurs with a 
frequency of 0.9%. Since repeated SLNB (and therefore further exposure to PBV) is increasingly being advocated for the small propor-
tion of patients who develop a local (in-breast) recurrence, and because anaphylaxis can be life-threatening, it is important that those 
individuals that are allergic to PBV are recognised on their first medical exposure. The measurement of serum mast-cell tryptase (MCT) 
and skin prick test (SPT) are used in the investigation of suspected anaphylaxis because positive results are supportive of type-1 medi-
ated hypersensitivity. Here we report the clinical features, MCT results and SPT results that pertain to a series of four patients referred 
to our drug allergy clinic with suspected anaphylaxis following SLNB. We recommend that all patients that show clinical evidence of 
allergy following exposure to PBV are referred to a specialist drug allergy service for further evaluation to investigate the cause.
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INTRODUCTION
Blue dyes, such as Patent Blue V (PBV), have been used in 
medical procedures worldwide for decades. In the UK, National 
Institute of Clinical Excellence guidelines recommend that 
sentinel lymph node biopsy (SLNB) is the preferred method 
for staging the axilla in early breast cancer and this should be 
performed using the combined localization technique of blue 
dye and radioactive tracer [1]. Reports of the association of blue 
dyes with anaphylaxis date since 1960s [2, 3]. The frequency 
of allergic reactions to PBV was recently reported as 0.9% in 
the 7,917 UK patients enrolled in NEW START and ALMANAC 
(ALMANAC was a multicentre randomised study that compared 
axillary lymphatic mapping against nodal axillary clearance 
and NEW START was a UK-wide sentinel node biopsy training 
programme) [4]. This figure is similar to the frequency estimates 
in older, smaller studies [5-8].
Allergy to PBV has been attributed to type-I hypersensitivity 
because the reactions occur in the right time frame, subjects 
with an appropriate clinical history show a positive result on 
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skin testing and the presence of a specific IgE to PBV has been 
demonstrated in a patient with a relevant history [5, 8-10]. It 
has been proposed that PBV acts as a hapten that binds to an 
unidentified carrier protein [11]. Since these reactions can arise on 
the first medical exposure, it is thought that sensitisation occurs 
as a result of exposure to blue dyes used in food, textiles and 
cosmetics [9, 10, 12]. 
In the course of general anaesthesia there are many potential 
causes for bronchospasm, hypotension, angioedema and urticaria, 
which may be allergic or non-allergic. Recognising allergic 
reactions caused by PBV can be particularly difficult because 
there is frequently not a clear temporal association between 
administering the drug and the onset of symptoms [13]. The 
Association of Anaesthetists of Great Britain and Ireland (AAGBI) 
guidelines state that anaphylaxis arising during anaesthesia should 
be managed with 50 µg intravenous (IV) boluses of adrenaline 
given as quickly as possible and appropriate volumes of 0.9% 
saline or Ringer’s solution used to maintain blood pressure [14]. 
It is recommended that once the patient has been stabilised 10 
mg of IV chlorpheniramine and 200 mg of IV hydrocortisone 
are administered. If blood pressure cannot be maintained 
on an adrenaline infusion an alternative vasopressor such as 
metaraminol is considered, depending on the experience of the 
anaesthetist. Blood samples should be taken for mast cell tryptase 
(MCT) as close to the event as practical, at 1-2 h and at baseline 
(24 h or more after the event). If anaphylaxis during anaesthesia is 
suspected, it is the anaesthetist’s responsibility to refer the patient 
to an allergy centre for investigation.
Anaphylactic reactions may be allergic (mediated by an immune 
mechanism) or non-allergic (previously called anaphylactoid). 
If the reaction is caused by type-1 hypersensitivity (i.e. it is IgE 
mediated), skin prick test (SPT) can be used to identify the causal 
drug. Recently a diagnostic protocol for investigating suspected 
allergic reactions to PBV by skin testing has been proposed [15]. 
Detecting a rise in serum MCT is helpful because it is indicative of 
mast cell degranulation and supports a diagnosis of drug allergy. 
Here we report the clinical features, MCT results and SPT results 
that pertain to a series of four patients referred to our drug allergy 
clinic (DAC) with suspected anaphylaxis following SLNB. 
CASE REPORTS
The patients were identified during an anaesthetic audit of 
critical incidents after they showed clinical evidence of immediate 
hypersensitivity during SLNB, from which they had all made a full 
recovery (Table 1). In accordance with the AAGBI guidelines the 
patients were referred for drug-allergy testing [14]. None had a 
known history of prior medical exposure to PBV. In the drug-allergy 
clinic SPT were performed in duplicate using a panel consisting 
of a positive control (histamine chloride, 10 mg/mL), a negative 
Table 1. Clinical characteristics and clinical features of allergic reactions to PBV in all four patients and their tryptase and SPT results
Case Age Time to 
reaction (min) HT BS URT ANG Grade* Sample 
time (h)
Tryptase
(ng/mL)
‡
Baseline 
tryptase
(ng/mL)
SPT
 (mm)
§
1 46 50 X X III
6
†
12
†
72
†
6.5
2.5
12.1
3.2 6
2 56 20 X X X III
Acute
12
24
<1
<1
<1
2 5
3 64 20 X X III
Acute
2
12
8.8
8.4
5.4
8.3 4
4 63 30 X III ND ND 1.5 6
PBV, Patent Blue V; SPT, skin prick test; HT, hypotension; BS, bronchospasm; URT, urticaria; ANG, angioedema; ND, not done. 
*Reactions were graded 
from I to IV using the criteria described by Barthelmes et al. [4]: grade I (urticaria, blue hives, pruritis or generalised rash); grade II (transient hypotension, 
bronchospasm or laryngospasm); grade III (severe hypotension requiring vasopressor support and/or change/abandoning of planned procedure and/
or high dependency unit/intensive therapy unit admission); grade IV (cardiorespiratory arrest and/or death). 
†Timing of samples uncertain - 3 samples 
were received by the laboratory and the following results were recorded: day 1 (6 h post reaction), 6.5 μg/L; day 2 (18 h post reaction), 2.5 μg/L; day 4 
(72 h post reaction), 12.1 μg/L. It is suspected there was a mix up in labelling the samples. 
‡Serum MCT was measured by fluorescent immunoassay (Im-
munocap, Phadia, normal range 2-14 ng/mL). Levels above 14 ng/mL or increased by a factor of three or more from baseline were considered increased. 
§A SPT result that was at least 3 mm greater than the negative control was considered positive.apallergy.org
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control (normal saline) and appropriate dilutions of all the other 
drugs to which they had been exposed (in each case hypnotics, 
muscle relaxants and opioids). PBV was used at vial concentration 
(25 mg/mL), which has previously been shown to be non-irritating 
[5, 13, 14]. A SPT result that was at least 3 mm greater than the 
negative control was considered positive. None of the patients 
showed any evidence of dermatographism with the negative 
control.
Case 1
Fifty min after blue dye was administered a 46-year-old woman 
developed an urticarial rash at the operative site and dropped her 
systolic BP to 70 mmHg - this responded rapidly to treatment with 
adrenaline IV boluses (total 50 μg). Peak MCT measured within 
the 72 h following her reaction was 12.1 ng/mL (baseline was 3.2, 
Table 1). In the DAC a 6 mm positive reaction was recorded on 
SPT with PBV in the context of a negative reaction to all the other 
drugs used and the negative control. She had no previous history 
of allergy or atopy.
Case 2
Twenty min after the administration of PBV a 56-year-old 
woman showed a drop in her systolic blood pressure to 70 
mmHg and lung compliance was noted to reduce. She developed 
laryngeal oedema. Sustained improved blood pressure and 
ventilation pressures were achieved after 1 h following the 
administration of chlorpheniramine, hydrocortisone, 5 mg of 
nebulised salbutamol, two litres of fluid and three 0.5 mg boluses 
of metaraminol. She was transferred to ICU from theatre, without 
the need for ongoing inotrophic support, and extubated the next 
day. Serial MCT showed no rise (Table 1). SPT a month later showed 
a positive response to PBV (5 mm) and negative response to all 
the other drugs tested. She reported a history of mild hay fever in 
the tree pollen season, but this was well controlled and was not 
investigated with SPT.
Case 3 
A 64-year-old woman developed hypotension and discrete 
areas of angioedema and wheals that stained blue with the dye 
shortly after PBV was administered. The intended surgery was 
abandoned. MCT taken at the time of the reaction was found to 
be 8.8, and was 8.4 and 5.4 ng/mL 2 h later and at baseline. Two 
months later on SPT she developed positive response (4 mm) to 
PBV only. She had no history of atopy but complained of nasal 
congestion and dizziness after eating food containing wheat. She 
did not show a reaction to wheat on SPT and had not consumed it 
on the day of her surgery.
Case 4
Thirty min after the administration of PBV a 63-year-old lady 
showed a drop in her systolic blood pressure to 65 mmHg. 
There was no cutaneous involvement and no laryngeal oedema 
or bronchospasm were reported. Sustained improvement was 
achieved with the administration of three 3 mg boluses of 
ephedrine, 200 mg of hydrocortisone, 10 mg of chlorpheniramine, 
one litre of crystalloid and 500 mL of colloid over a period of 30 
min. When seen in the DAC 6 weeks later, she showed a 6 mm 
positive response on SPT with PBV; her response to all other drugs 
tested was negative. She had a history of mild asthma and allergy/
intolerance to ibuprofen (wheeze occurring within 2 h of ingestion 
on two occasions without any other associated features).
DISCUSSION
All of the cases described here had clinical histories consistent 
with anaphylaxis, showed positive SPT tests to PBV, and did not 
show a reaction with any of the other drugs used. Although 
the negative predictive value for SPT with any drug is not 100% 
(and therefore there is a chance that one of the other drugs 
administered concurrently caused the reaction), it is known that 
only a small proportion of control individuals show a positive 
reaction to PBV on skin testing (15/566 (2.6%) in the study by 
Kalimo et al. [5]), suggesting that false positives to PBV are quite 
rare. Therefore, on the balance of probabilities PBV is the most 
likely causal agent for the anaphylactic reaction in each case. 
In common with the previously published case series, also 
derived from patients attending DACs, our patients showed 
relatively severe (grade III) reactions. This is in contrast to the 
observed rates in NEW START/ALMANAC where the milder grade 
I and II reactions were more common than the severe grade 
III reactions (grade I had a frequency of 0.3%, grade II 0.2%, 
grade III 0.06% and grade IV 0%). Given that allergy to PBV was 
a prospectively collected, predefined data point in NEW START/
ALMANAC, the quoted rates of allergy are likely to be accurate. 
While these numbers are too small to draw any firm conclusions, it 
is possible that this discrepancy represents a referral bias, with the 
less severe reactions not being referred for drug-allergy testing. apallergy.org
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This is of concern because repeated SLNB (and therefore further 
exposure to PBV) is increasingly being advocated for the small 
proportion of patients who develop a local (in-breast) recurrence. 
There are several reports in the literature of individuals who have 
had more than one reaction to PBV, the first one not having been 
recognised or correctly attributed to the dye [8, 12, 13, 16]. 
In our series of four patients, none showed a MCT peak that was 
above the upper limit of normal although one showed a greater 
than 3-fold increase. This in keeping with a recent study which 
reports the sensitivity of MCT measurement following anaphylaxis 
to PBV is just 0.54 [17]. 
In summary, in common with the other published case series, 
we found that the majority of patients referred with suspected 
PBV allergy seen in our DAC had experienced relatively severe 
reactions. A rise in MCT is of limited sensitivity in identifying 
patients who show evidence of type-1 hypersensitivity to PBV 
and we recommend that whenever there is a clinical suspicion of 
anaphylaxis associated with PBV the patient is referred to specialist 
drug allergy services for further assessment. 
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